Pharma
-
Novartis radiopharmaceutical drug succeeds in first-line gut cancer study
Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.
By Jonathan Gardner • Sept. 25, 2023 -
New Alzheimer's drugs
Eisai’s Alzheimer’s drug Leqembi approved in Japan
Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.
By Ned Pagliarulo • Sept. 25, 2023 -
Explore the Trendline➔
luismmolina via Getty ImagesTrendlineThe expanding world of RNA therapies
Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.
By BioPharma Dive staff -
Sponsored by Viatris
Driving innovation to benefit people living with MS
A holistic approach to R&D is key to support MS patients throughout their treatment journey.
By Pat Vallano, Ph.D., Head of Innovative Programs, R&D, Viatris • Sept. 25, 2023 -
AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors
Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.
By Jonathan Gardner • Sept. 22, 2023 -
Alvotech gets new FDA review for Humira biosimilar
The regulator has twice rejected Alvotech’s copycat drug due to manufacturing issues with a plant in Europe.
By Jonathan Gardner • Sept. 20, 2023 -
PBMs, PhRMA trade blame over drug costs in House hearing
Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.
By Rebecca Pifer • Sept. 19, 2023 -
Novartis cancels Beigene partnership as cancer drug gains EU approval
The terminated deal leaves Novartis without a PD-1 inhibitor nine years after Merck’s Keytruda won its first approval.
By Jonathan Gardner • Sept. 19, 2023 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
FTC takes aim at pharma patent tactics used to block generics
The antitrust regulator is examining what it describes as abuse of the FDA “Orange Book” — another step in its scrutiny of pharma business practices.
By Jonathan Gardner • Sept. 15, 2023 -
FDA approves updated COVID boosters from Pfizer, Moderna
Pfizer and Moderna, which have seen slowing demand for their coronavirus vaccines, expect their reformulated shots will soon be available in the U.S.
By Delilah Alvarado • Sept. 11, 2023 -
Novartis stops work on gene therapy acquired in Gyroscope deal
The decision follows a review by a trial monitoring committee, which concluded data for the geographic atrophy treatment didn't support further development.
By Delilah Alvarado • Sept. 11, 2023 -
Manufacturing delays under-the-skin Tecentriq shot in US
Roche says it won’t be able to launch the subcutaneous version of the drug until 2024 as it works with the FDA on manufacturing updates.
By Jonathan Gardner • Sept. 8, 2023 -
Moderna says updated COVID shot likely to protect against worrisome variant
The findings add to early evidence showing a heavily mutated variant called BA.2.86, which is growing in prevalence, may not be as evasive as scientists once feared.
By Delilah Alvarado • Sept. 6, 2023 -
Roche claims study success for targeted drug in early lung cancer
The Swiss pharma said, without details, that it observed “unprecedented” results that could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.
By Ben Fidler • Sept. 1, 2023 -
Sanofi appoints a venture investor to R&D head as executive team expands
Houman Ashrafian, currently a scientific advisor at SV Health Investors, will fill the role left by John Reed, who oversaw the transformation of research and development during his five years at Sanofi.
By Jacob Bell • Aug. 31, 2023 -
Sponsored by ZS
The intelligent content ecosystem is here. Is your organization ready?
Is pharma up to the challenge of delivering the personalized and contextual experiences doctors have come to expect? Too often, the answer is no.
By Saby Mitra, Global Digital Customer Experience Practice Leader at ZS • Aug. 28, 2023 -
Roche’s surprise study results spur new optimism for TIGIT drugs
Data inadvertently published from a closely watched lung cancer study suggest a drug blocking the protein TIGIT may help extend survival, a finding that boosted shares of other developers.
By Jonathan Gardner • Aug. 23, 2023 -
Sponsored by Phil
8 key components of a telemedicine program that delivers an exceptional patient experience
Discover how to accelerate patient access and commercial success through a best-in-class telemedicine program.
Aug. 21, 2023 -
Moderna builds case for updated COVID shot ahead of latest booster push
But the demand for booster shots ahead of an expected surge of infections this fall remains an unanswered question weighing heavily on Moderna’s future outlook.
By Jonathan Gardner • Aug. 18, 2023 -
Merck says drug acquired in $1B buyout scores in large kidney cancer study
The treatment, which Merck picked up through a 2019 acquisition of Peloton Therapeutics, helped delay disease progression in patients with advanced renal cell carcinoma.
By Jacob Bell • Aug. 18, 2023 -
Obesity drugs
Boehringer moves Wegovy competitor into late-stage testing
The German pharmaceutical company is launching three Phase 3 trials of an obesity drug called survodutide, which like Wegovy targets the GLP-1 receptor
By Ned Pagliarulo • Aug. 17, 2023 -
Amazon Pharmacy expands insulin manufacturer coupons
The new coupons include some of the most commonly prescribed diabetes drugs from Eli Lilly, Novo Nordisk and Sanofi.
By Rebecca Pifer • Aug. 17, 2023 -
Gilead antibody drug shows signs of potential in early lung cancer
A combination of Trodelvy and Merck’s Keytruda appears active against lung tumors, but has a high bar to clear and faces competition from AstraZeneca and Daiichi Sankyo.
By Jonathan Gardner • Aug. 17, 2023 -
Q&A
A leading Democrat reveals how his mental health struggles shape his policy approach
Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.
By Karissa Waddick • Aug. 17, 2023 -
FDA approves bispecific drug from Pfizer for multiple myeloma
Elrexfio is the third bispecific antibody cleared to treat the cancer, and will compete with other therapies that target the “BCMA” protein on myeloma cells.
By Jonathan Gardner • Aug. 14, 2023 -
FDA delays decision on Valneva’s chikungunya vaccine
The agency needs more time to settle with Valneva the design of a post-marketing study for the shot, which could become the first preventive therapy for chikungunya available in the U.S.
By Delilah Alvarado • Aug. 14, 2023